The coagulation/fibrinolysis balance in systemic sclerosis: Evidence for a haematological stress syndrome

British Journal of Rheumatology

Volumn 36, Issue 10, 1997, Pages 1045-1050

  Ames, P R J ^a   Lupoli, S ^c   Alves, J ^b   Atsumi, T ^a   Edwards, C ^a   Iannaccone, L ^c   Khamashta, M A ^a   Hughes, G R V ^a   Brancaccio, V ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL CURRY CABRAL   (Portugal)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

Coagulation; Fibrinolysis; Systemic sclerosis

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARAN SULFATE; LIPOPROTEIN A; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL WALL; CLINICAL ARTICLE; COMPLEX FORMATION; FEMALE; FIBRIN DEPOSITION; FIBRIN FORMATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SYSTEMIC SCLEROSIS;

EID: 0030725625     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.10.1045     Document Type: Article

References (45)

1. Black CM, Stephens CO. Scleroderma-systemic sclerosis. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford textbook of rheumatology. Vol. 2. Oxford University Press, 1993:771-89.
2. Campbell PM, Leroy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975;4:351-68.
3. Kahaleh MB. Vascular disease in scleroderma. Rheum Dis Clin North Am 1990;16:53-7.
4. Kahaleh MB, Osborn I, Le Roy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94: 482-4.
5. Greaves M, Malia RG, Ward MA et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br J Rheumatol 1988;27:281-5.
6. Herrick AL, Illingworth K, Blann A, Hay CRM, Hollis S, Jayson MIV. Von Willebrand factor, thrombomodulin, thromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;5:122-7.
7. Falanga V, Kruskal JB, Franks JJ. Fibrin and fibrinogen-related antigens in systemic sclerosis (scleroderma). J Am Acad Dermatol 1991;25:771-5.
8. Cunliffe WJ, Menon IS. Blood fibrinolytic activity in diseases of small blood vessels and the effect of low molecular weight dextran. Br J Dermatol 1969;81: 220-9.
9. Holland CD, Jayson MIV. Venous blood fibrinolysis and fibrinolytic potential in primary Raynaud's phenomenon and systemic scleroderma associated Raynaud's phenomenon. In Black CM, Myers AR, eds. Systemic sclerosis. New York: Gower Medical Publisher Limited, 1985:267-74.
10. Browse NI, Gray L, Jarret PEM et al. Blood and vein wall fibrinolytic activity in health and in vascular diseases. Br Med J 1977;1:478-83.
11. Keegan AC, Holland CD, Jayson MIV. Loss of diurnal variation in fibrinolytic activity in Systemic Sclerosis. Br J Rheumatol 1985;24:21 (Abstract).
12. Matucci-Cerinic M, Lotti T, Iombardi A, Pignone A, Iannone F, Beneforti E et al. Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation. Int J Dermatol 1990;29:644-7.
13. Lotti T, Matucci-Cerinic M, Marmugi D et al. Cutaneous fibrinolytic activity in scleroderma. Clin Exp Rheumatol 1985;3:248-51.
14. Scanu AM, Fless GM. Lipoprotein (a): heterogeneity and biological relevances. J Clin Invest 1990;85:1705-15.
15. Dawes KE, Gray AJ, Laurent GI. Thrombin stimulates fibroblast chemotaxis and replication. Eur J Cell Biol 1993;61:126-30.
16. Senior RM, Skogen WF, Griffin GL et al. Effects of fibrinogen derivatives upon the inflammatory response. J Clin Invest 1986;77:1014-9.
17. Collins PW, Macey MG, Cahill MR, Newland AC. Von Willebrand factor release and P-selectin expression is stimulated by thrombin and trypsin but not IL-1 in cultured human endothelial cells. Thromb Haemostasis 1993;70:346-50.
18. American Rheumatism Association Subcommittee for Scleroderma. Criteria of the Therapeutic Criteria Committee, preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
19. Clauss A. Gerinnungphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-42.
20. Lee JE, Haynes JM. Carotid arteries and cerebral infarction due to scleroderma. Neurology 1967;17: 18-22.
21. Reidy ME, Steen V, Nicholas JJ. Lower extremity amputation in scleroderma. Arch Phys Med Rehabil 1992;73:811-3.
22. Dorevitch MI, Clemens LE, Webb JB. Lower limb amputation secondary to large vessel involvement in scleroderma. Br J Rheumatol 1988;27:403-6.
23. Martin L, Pauls JD, Ryan JP, Fritzler MJ. Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone. Ann Rheum Dis 1993;52:780-4.
24. Youssef P, Englert H, Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis 1993;52:464-6.
25. Belch JJ, Veale DJ, Colleridge T. Large vessel disease in CREST [Letter]. Ann Rheum Dis 1993;52:837-8.
26. Goodfield MJ, Orchard MA, Rowell NR. Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Haematol 1993;84:675-80.
27. Howard GC, Pizzo SV. Biology of disease. Lipoprotein (a) and its role in atherothrombotic disease. Lab Invest 1994;64:373-85.
28. Gruden G, Cavallo-Perin P, Romagnoli R, Olivetti C, Frezet D, Pagano G. Prothrombin fragment 1 + 2 and antithrombin III-thrombin complex in microalbuminuric type II diabetic patients. Diabetes Med 1993;11:485-8.
29. Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with anti-phospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994;83:2532-40.
30. Ames PRJ, Iannaccone L, Tommasino C, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic anti-phospholipid antibodies. A crucial role for acquired free protein S deficiency. Thromb Haemostasis 1996;76:190-4.
31. Marsen TA, Simonson MS, Dunn MJ. Thrombin induces the preproendothelin-1 gene in endothelial cells by a protein tyrosine kinase-linked mechanism. Circ Res 1995;76:987-95.
32. Kahaleh MB. Endothelin, an endothelial dependent vasoconstrictor in scleroderma. Enhanced production and pro-fibrotic action. Arthritis Rheum 1991;34: 978-83.
33. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994;53:506-10.
34. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987;79:117-23.
35. Holt CM, Lindsey N, Moult J, Malia RG, Greaves M, Hume N et al. Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol 1989;78:359-65.
36. Meade TW, Vickers MV, Thompson SG, Seghatchian MJ. The effect of physiological levels of fibrinogen on platelets aggregation. Thromb Res 1985;38:527-34.
37. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor on plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
38. Pearson JD. Antibodies to endothelial cells and vascular dysfunction in progressive systemic sclerosis and mixed conective tissue disease. In: Cervera P, Khamashta MA, Hughes GRV, eds. Antibodies to endothelial cells and vascular damage. Boca Raton, FL: CRC Press, Inc., 1994:111-9.
39. Ernst E. Fibrinogen as a cardiovascular risk factor-interrelationship with infections and inflammation. Eur Heart J 1993;14(Suppl. K):82-7.
40. Juhan Vague I, Aillaud MF, De Cock F, Philip-Joet C, Arnaud C, Serradgmi A et al. The fast-acting inhibitor of tissue type plasminogen activator is an acute phase reactant protein. In: Davidson JF, Donati MB, Coccheri S, eds. Progress in fibrinolysis. Vol. VII. Edinburgh: Churchill Livingstone, 1985: 146-9.
41. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. Von Willebrand factor is an acute phase reactant in man. Thromb Res 1989;53:387-94.
42. Sironi M, Breviario F, Proserpio P, Biondi A, Vecchi A, Van Damme J et al. IL-1 stimulated IL-6 production in endothelial cells. J Immunol 1989;142:549-56.
43. Reizenstein P. The haematological stress syndrome. Br J Haematol 1979;43:329-34.
44. Stuart J, George AJ, Davies AJ, Auckland A, Hurlow RA. Haematological stress syndrome in atherosclerosis. J Clin Pathol 1981;34:464-7.
45. Hernandez-Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM et al. Role of thrombin in pulmonary fibrosis. Lancet 1995;346:1071-3.